表紙
市場調査レポート

中国の組み換えタンパク質医薬品産業レポート

China Recombinant Protein Drug Industry Report, 2014-2017

発行 ResearchInChina 商品コード 319454
出版日 ページ情報 英文 127 Pages
納期: 即日から翌営業日
価格
本日の銀行送金レート: 1USD=102.85円で換算しております。
Back to Top
中国の組み換えタンパク質医薬品産業レポート China Recombinant Protein Drug Industry Report, 2014-2017
出版日: 2014年11月19日 ページ情報: 英文 127 Pages
概要

中国の組み換えタンパク質医薬品市場は、需要の高まりや消費能力の向上などから、急速に拡大しています。2014年には、400億人民元を越える需要が期待できると予測されています。

当レポートでは、中国の組み換えタンパク質医薬品産業について調査分析し、概要、発展状況、市場区分、主要企業などについて、体系的な情報を提供しています。

第1章 組み換えタンパク質医薬品産業の概要

  • 定義
  • 分類

第2章 中国の組み換えタンパク質医薬品の発展

  • 世界市場
  • 世界市場区分
  • 中国市場
  • 見通し

第3章 中国の組み換えタンパク質医薬品市場区分

  • 組み換えインスリン
  • 組み換えヒトインターフェロン(rhIFN)
  • 組み換えヒト顆粒球コロニー刺激因子(rhG-CSF)
  • 組み換えヒト卵胞刺激ホルモン(rhFSH)
  • 組み換えヒトエリスロポエチン(rhEPO)
  • 組み換えヒト成長ホルモン(rhGH)
  • その他

第4章 中国の組み換えタンパク質の主要企業

  • 3SBio Inc.
  • Uni-Bio Science Group Limited
  • Shenzhen Neptunus Interlong Bio-Technique Co., Ltd.
  • Essex Bio-Technology Limited
  • Livzon Pharmaceutical Group Inc.
  • Changchun High & New Technology Industry (Group) Inc.
  • Anhui Anke Biotechnology (Group) Co., Ltd.
  • Tonghua Dongbao Pharmaceutical Co., Ltd.
  • Beijing SL PHarmaceutical Co., Ltd.
  • Jiangsu Shihuan Bioengineering Co., Ltd.

第5章 サマリーと予測

  • サマリー
  • 予測

図表

目次
Product Code: ZYM060

The Chinese recombinant protein drug market has been expanding rapidly owing to the improvement of demand rigidity, consumption ability and the like. During 2005-2013, sales of recombinant protein drugs available in Chinese sample hospitals grew at a CAGR of 19.1%, and it is projected that China will see its actual demand for recombinant protein drugs exceed RMB40 billion in 2014.

The start of recombinant protein drugs in China is not late and common drugs are diversified in variety, for example, recombinant human erythropoietin (rhEPO), recombinant human granulocyte colony-stimulating factor (rhG-CSF) and recombinant human interferon (rhIFN) have gained market approval in the 1990s. Moreover, in 2013, domestic rhG-CSF, rhEPO andrecombinant human growth hormone (rhGH) with price advantage took a respective share of 82.1%, 88.5% and 90.2% in Chinese sample hospitals, and recombinant human interleukin-2/11(rhIL-2/11) was fully localized.

However, as compared with products from leading bio-pharmaceutical enterprises in the United States and Europe, domestic recombinant protein drugs are still characterized by low-end technologies and largely remain in common short-acting areas. And foreign brands still prevail in the markets of recombinant insulin, rhIFN, recombinant coagulation factor and recombinant human follicle-stimulating hormone (rhFSH).

1. Recombinant Insulin Market. In 2013,foreign brands such asNovo Nordisk's insulin aspart and insulin detemir, Sanofi's insulin glargine, Eli Lilly's insulin lispro accounted for 91.4% of recombinant insulin market of Chinese sample hospitals, while domestic insulin e.g. insulin glargine and insulin lispro of Gan & Lee Pharmaceuticals, recombinant insulin of Tonghua Dongbao Pharmaceuticaland animal insulin of Wanbang Biopharmaceuticalswas at a distinct disadvantage, whereas insulin analog products of Gan & Lee are still in the process of development, with huge potential for growth in the future.

2. rhIFN-αMarket.Roche's PEG-IFNα-2a, MSD's PEG-IFNα-2a and IFN-α-2a, and other imported products still dominate Chinese interferon market, sweeping as much as 70.7% of recombinant interferon market of sample hospitals in 2013; whilemore than a dozen local companies like Shanghai Huaxin High Biotechnology Inc., Beijing Tri-Prime Genetic Engineering Co., Ltd. and Anhui Anke Biotechnology (Group) Co., Ltd.mainly produce ordinary short-acting products, which lack strong competitiveness compared with PEG-Intron products (long-acting interferon)with better anti-hepatitisvirus effect.

Moreover, there is no domestic recombinant protein drug in such markets as rhIFN-β, rhFSH, recombinant coagulation factor VIIa and factorVIIIyet.

Based on support from favorable policies, R&D ability enhancement as well as being optimistic about market prospects, a large number of biotech companies are vigorously developing long-acting, high-end protein drugs.

In August 2014, PEG-rhGHof GeneScience Pharmaceuticals Co., Ltd. (GenSci, a subsidy of Changchun High & New Technology Industry (Group) Inc.) obtained the GMP certificate and could formally go on sale; however, as PEG-rhGHbelongs to national new First-in-Class drugs, a phase IV clinical trial is a must, and mass production is expected to begin in 2016. In June 2014, Anke Biotechnology's PEG-rhIFNαand Dongbao Pharmaceutical'sultrolente insulin (insulin glargine)were both approved for clinical application. So far,PEG-GCSF of Jiangsu Hengrui Medicine Co., Ltd., PEG-rhIFNαof Xiamen Amoytop Biotech Co., Ltd. (a subsidiary of Dongbao Pharmaceutical) and rhFSH of GenSci have all declared for production and are expected to be approved and availableon the market in 2015.

image1

China Recombinant Protein Drug Industry Report, 2014-2017 highlights the followings:

  • Market size, competition pattern, market segments, prospects, etc. of recombinant protein drugs worldwide;
  • Market situation, competition pattern, R&D, forecasts for2014-2017, etc. of recombinant protein drugs in China;
  • Development status, competition pattern, prospects, etc. of product segments e.g. recombinant insulin, rhG-CSF, rhEPO, rhGH, rhFSH in China;
  • Operation, recombinant protein drug business, forecast, etc. of 10 keyrecombinant protein drug enterprises in China (including Anhui Anke Biotechnology (Group) Co., Ltd., 3SBio Inc., Livzon Pharmaceutical Group Inc., Tonghua Dongbao Pharmaceutical Co., Ltd., etc.).

Table of Contents

1. Overview of Recombinant Protein Drug Industry

  • 1.1 Definition
  • 1.2 Classification

2. Development of Recombinant Protein Drugs in China

  • 2.1 Market Worldwide
  • 2.2 Market Segments Worldwide
    • 2.2.1 Insulin
    • 2.2.2 Recombinant Human Interferon (rhIFN)
    • 2.2.3 Recombinant Human Erythropoietin (rhEPO)
    • 2.2.4 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
    • 2.2.5 Recombinant Human Growth Hormone (rhGH)
    • 2.2.6 Recombinant Human Follicle-stimulating Hormone (rhFSH)
  • 2.3 Market in China
    • 2.3.1 Market Size
    • 2.3.2 Competition Pattern
  • 2.4 Prospects
    • 2.4.1 Market Worldwide
    • 2.4.2 Market in China

3. Recombinant Protein Drug Market Segments in China

  • 3.1 Recombinant Insulin
    • 3.1.1 Development Status
    • 3.1.2 Competition Pattern
    • 3.1.3 Prospects
  • 3.2 Recombinant Human Interferon (rhIFN)
    • 3.2.1 Development Status
    • 3.2.2 Competition Pattern
    • 3.2.3 Prospects
  • 3.3 Recombinant Human Granulocyte Colony-stimulating Factor (rhG-CSF)
    • 3.3.1 Development Status
    • 3.3.2 Competition Pattern
    • 3.3.3 Prospects
  • 3.4 Recombinant Human Follicle-stimulating Hormone (rhFSH)
    • 3.4.1 Development Status
    • 3.4.2 Competition Pattern
    • 3.4.3 Prospects
  • 3.5 Recombinant Human Erythropoietin (rhEPO)
    • 3.5.1 Development Status
    • 3.5.2 Competition Pattern
    • 3.5.3 Prospects
  • 3.6 Recombinant Human Growth Hormone (rhGH)
    • 3.6.1 Development Status
    • 3.6.2 Competition Pattern
    • 3.6.3 Prospects
  • 3.7 Others
    • 3.7.1 Recombinant Coagulation Factor
    • 3.7.2 Interleukin

4. Major Recombinant Protein Companies in China

  • 4.1 3SBio Inc.
    • 4.1.1 Profile
    • 4.1.2 Operation
    • 4.1.3 Revenue Structure
    • 4.1.4 Gross Margin
    • 4.1.5 R&D and Investment
    • 4.1.6 Recombinant Protein Business
  • 4.2 Uni-Bio Science Group Limited
    • 4.2.1 Profile
    • 4.2.2 Operation
    • 4.2.3 Revenue Structure
    • 4.2.4 Gross Margin
    • 4.2.5 R&D and Investment
    • 4.2.6 Recombinant Protein Business
    • 4.2.7 Major Clients and Suppliers
  • 4.3 Shenzhen Neptunus Interlong Bio-Technique Co., Ltd.
    • 4.3.1 Profile
    • 4.3.2 Operation
    • 4.3.3 Revenue Structure
    • 4.3.4 Gross Margin
    • 4.3.5 R&D and Investment
    • 4.3.6 Recombinant Protein Business
    • 4.3.7 Major Clients and Suppliers
  • 4.4 Essex Bio-Technology Limited
    • 4.4.1 Profile
    • 4.4.2 Operation
    • 4.4.3 Gross Margin
    • 4.4.4 Recombinant Protein Business
    • 4.4.5 Major Clients and Suppliers
  • 4.5 Livzon Pharmaceutical Group Inc.
    • 4.5.1 Profile
    • 4.5.2 Operation
    • 4.5.3 Revenue Structure
    • 4.5.4 Gross Margin
    • 4.5.5 Clients
    • 4.5.6 R&D and Investment
    • 4.5.7 Recombinant Protein Business
    • 4.5.8 Outlook and Forecast
  • 4.6 Changchun High & New Technology Industry (Group) Inc.
    • 4.6.1 Profile
    • 4.6.2 Operation
    • 4.6.3 Revenue Structure
    • 4.6.4 Gross Margin
    • 4.6.5 Clients
    • 4.6.6 R&D and Investment
    • 4.6.7 Recombinant Protein Business
    • 4.6.8 Outlook and Forecast
  • 4.7 Anhui Anke Biotechnology (Group) Co., Ltd.,
    • 4.7.1 Profile
    • 4.7.2 Operation
    • 4.7.3 Revenue Structure
    • 4.7.4 Gross Margin
    • 4.7.5 Clients
    • 4.7.6 R&D and Investment
    • 4.7.7 Recombinant Protein Business
    • 4.7.8 Outlook and Forecast
  • 4.8 Tonghua Dongbao Pharmaceutical Co., Ltd.
    • 4.8.1 Profile
    • 4.8.2 Operation
    • 4.8.3 Revenue Structure
    • 4.8.4 Gross Margin
    • 4.8.5 Clients
    • 4.8.6 R&D and Investment
    • 4.8.7 Recombinant Protein Business
    • 4.8.8 Outlook and Forecast
  • 4.9 Beijing SL PHarmaceutical Co., Ltd.
    • 4.9.1 Profile
    • 4.9.2 Operation
    • 4.9.3 Revenue Structure
    • 4.9.4 Gross Margin
    • 4.9.5 Clients
    • 4.9.6 R&D and Investment
    • 4.9.7 Recombinant Protein Business
    • 4.9.8 Outlook and Forecast
  • 4.10 Jiangsu Shihuan Bioengineering Co., Ltd.
    • 4.10.1 Profile
    • 4.10.2 Operation
    • 4.10.3 Revenue Structure
    • 4.10.4 Gross Margin
    • 4.10.5 Clients
    • 5.10.6 R&D and Investment
    • 4.10.7 Recombinant Protein Business
    • 4.10.8 Outlook and Forecast

5. Summary and Forecast

  • 5.1 Summary
  • 5.2 Forecast

Selected Charts

  • Production Process of Recombinant Protein Drugs
  • Classification and Indications of Recombinant Protein Drugs
  • Market Size and YoY Growth of Recombinant Protein Drugs Worldwide, 2007-2014
  • Competition Pattern of Recombinant Protein Drugs Worldwide (by Product), 2013
  • Competition Patternof Recombinant Protein Drugs Worldwide (by Enterprise), 2013
  • Classification of Insulin (by Technological Levelor Time)
  • Market Size and YoY Growth of Insulin Worldwide, 2007-2014
  • Competition Pattern of Insulin Worldwide (by Enterprise), 2013
  • Market Size of Interferon Worldwide, 2007-2014
  • Competition Pattern of Interferon Worldwide (by Product or Enterprise), 2013
  • Market Size of rhEPO Worldwide, 2007-2014
  • Competition Pattern of rhEPO Worldwide (by Product or Enterprise), 2013
  • Market Size of rhG-CSF Worldwide, 2007-2014
  • Competition Patternof rhG-CSF Worldwide (by Product or Enterprise), 2007-2014
  • rhGH Indications Approved in the U.S. and China up to Now
  • Market Size of rhGH Worldwide, 2007-2014
  • Competition Pattern of rhGH Worldwide (by Product or Enterprise), 2007-2014
  • Sales of Recombinant Protein Drugs of Sample Hospitals in China, 2007-2014
  • Competition Pattern of Recombinant Protein Drugs of Sample Hospitals in China (by Product), 2013
  • Percentage of Domestic and Imported Recombinant Protein Drugs of Sample Hospitals in China (by Amount), 2007-2014
  • Competition Patternof Recombinant Protein Drugs of Sample Hospitals in China (by Enterprise), 2013
  • Number of Diabetics in China, 2011-2013
  • Market Size of Insulin Drugs in China, 2007-2014
  • Competition Pattern of Insulin Market in China (by Enterprise), 2013
  • Market Size of Insulin Drugs in China, 2013-2017E
  • Competition Patternof rhIFN of Sample Hospitals in China (by Product), 2013
  • Market Size of rhIFN in China, 2007-2014
  • Competition Pattern of rhIFN of Sample Hospitals in China (by Enterprise), 2013
  • Prices of Major Interferon Products in China, 2013-2014
  • Forecast for Market Capacity of rhIFN for Hepatitis Treatment in China
  • R&D of Major Interferon Products in China as of end-Sept. 2014
  • Competition Patternof rhG-CSF of Sample Hospitals in China (by Enterprise), 2013
  • Diseases Lethal to Rural Residents in China, 2012
  • R&D of Major PEG-rhG-CSF in China as of end-Sept. 2014
  • Costs of Treatment with Major FSH Products in China, 2012-2014
  • Competition Patternof FSH of Sample Hospitals in China (by Enterprise), 2013
  • Costs of Treatmentwith Major EPO Products in China
  • Market Competition Pattern of rhGH of Sample Hospitals in China (by Enterprise), 2013
  • Costs of Treatment with Major rhGH Products in China, 2012-2014
  • Lot Release Quantity and Growth Rate of Coagulation Factor VIII in China, 2008-2013
  • Revenue and Profit of 3SBio, 2007-2012
  • Revenue Structure of 3SBio, 2007-2012
  • Revenue Breakdown of 3SBio(by Product), 2007-2012
  • Gross Profit and Consolidated Gross Margin of 3SBio, 2007-2012
  • R&D Costs and % of Total Revenue of 3SBio, 2008-2012
  • R&D Cost Structure of 3SBio, 2008-2012
  • R&D Costs of 3SBio (by Product), 2008-2012
  • Key R&D Business of 3SBio, 2013
  • Major Recombinant Protein Products of 3SBio
  • Revenue and Profit of Uni-Bio Science, FY2008-FY2014
  • Revenue Structure of Uni-Bio Science (by Industry), FY2008-FY2014
  • Revenue Breakdown of Uni-Bio Science (by Industry), FY2008-FY2014
  • Gross Profit and Gross Margin of Uni-Bio Science, FY2008-FY2014
  • Products under R&D and Progress of Uni-Bio Science, FY2014
  • Uni-Bio Science's Revenue and Pretax Profit from Biological Drugs, FY2008-FY2014
  • Uni-Bio Science's Revenue Percentage from Top 5 Clients, FY2008-FY2014
  • Uni-Bio Science's Procurement Percentage from Top 5 Suppliers, FY2008-FY2014
  • Revenue and Net Income of Neptunus Interlong Bio-Technique, 2008-2014
  • Revenue Structure of Neptunus Interlong Bio-Technique (by Product), 2009-2014
  • Revenue Breakdown of Neptunus Interlong Bio-Technique (by Product), 2009-2014
  • Gross Profit and Gross Margin of Neptunus Interlong Bio-Technique, 2008-2014
  • Neptunus Interlong Bio-Technique's Revenue Percentage from Top 5 Clients, 2011-2013
  • Neptunus Interlong Bio-Technique's Procurement Percentage from Top 5 Suppliers, 2011-2013
  • Revenue and Net Income of Essex Bio-Technology, 2009-2014
  • Gross Profit and Gross Margin of Essex Bio-Technology, 2009-2014
  • Recombinant Protein Products of Essex Bio-Technology
  • Essex Bio-Technology's Revenue Percentage from Top 5 Clients, 2009-2014
  • Essex Bio-Technology's Procurement Percentage from Top 5 Suppliers, 2009-2014
  • Revenue and Net Income of Livzon Pharmaceutical Group, 2008-2014
  • Operating Revenue Structure of Livzon Pharmaceutical Group (by Region), 2008-2014
  • Revenue Breakdown of Livzon Pharmaceutical Group (by Region), 2008-2014
  • Operating Revenue Structure of Livzon Pharmaceutical Group (by Product), 2008-2013
  • Revenue Breakdown of Livzon Pharmaceutical Group (by Product), 2008-2013
  • Livzon Pharmaceutical Group's Revenue Breakdown and Percentage by Products, 2014H1
  • Consolidated Gross Margin of Livzon Pharmaceutical Group, 2008-2014
  • Gross Margin of Livzon Pharmaceutical Group (by Product), 2008-2013
  • Gross Margin of Livzon Pharmaceutical Group (by Product), 2014H1
  • Livzon Pharmaceutical Group's Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
  • Revenue and Gross Margin of Gonadotropin Products of Livzon Pharmaceutical Group, 2008-2014
  • Revenue and Net Income of Livzon Pharmaceutical Group, 2014-2017E
  • Revenue and Net Income of Changchun High & New Technology, 2008-2014
  • Operating Revenue Structure of Changchun High & New Technology (by Region), 2008-2014
  • Revenue Breakdown of Changchun High & New Technology (by Region), 2008-2014
  • Operating Revenue Structure of Changchun High & New Technology (by Industry), 2008-2014
  • Revenue Breakdown of Changchun High & New Technology (by Industry), 2008-2014
  • Consolidated Gross Margin of Changchun High & New Technology, 2008-2014
  • Gross Margin of Changchun High & New Technology (by Region), 2008-2014
  • Gross Margin of Changchun High & New Technology (by Industry), 2008-2014
  • Changchun High & New Technology's Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
  • Progress of R&D Projects of Changchun High & New Technology, as of June 2014
  • Changchun High & New Technology's Revenue from Biological Drugs and % of Total Revenue, 2008-2014
  • Gross Margin of Biological Drugs of Changchun High & New Technology, 2008-2014
  • Revenue and Net Income of GenSci, 2009-2014
  • Consolidated Gross Margin of GenSci, 2009-2014
  • Revenue and Net Income of Changchun High&New Technology, 2014-2017E
  • Revenue and Net Income of Anhui Anke Biotechnology, 2008-2014
  • Operating Revenue Structure of Anhui Anke Biotechnology (by Region), 2008-2014
  • Revenue Breakdown of Anhui Anke Biotechnology (by Region), 2008-2014
  • Operating Revenue Structure of Anhui Anke Biotechnology in China (by Region), 2009-2014
  • Revenue Breakdown of Anhui Anke Biotechnology in China (by Region), 2009-2014
  • Operating Revenue Structure of Anhui Anke Biotechnology (by Industry), 2008-2014
  • Revenue Breakdown of Anhui Anke Biotechnology (by Industry), 2008-2014
  • Consolidated Gross Margin of Anhui Anke Biotechnology, 2008-2014
  • Gross Margin of Anhui Anke Biotechnology (by Region), 2008-2014
  • Gross Margin of Anhui Anke Biotechnology (by Industry), 2008-2014
  • Anhui Anke Biotechnology's Revenue from Top 5 clients and % of Total Revenue, 2009-2014
  • R&D Costs and % of Total Revenue of Anhui Anke Biotechnology, 2008-2013
  • Anhui Anke Biotechnology's Revenue from Interferon and % of Total Revenue, 2009-2014
  • Gross Margin of Interferon of Anhui Anke Biotechnology, 2009-2014
  • Anhui Anke Biotechnology's Revenue from GH and % of Total Revenue, 2009-2014
  • Gross Margin of GH of Anhui Anke Biotechnology, 2009-2014
  • Revenue and Net Income of Anhui Anke Biotechnology, 2014-2017E
  • Revenue and Net Income of Dongbao Pharmaceutical, 2008-2014
  • Operating Revenue Structure of Dongbao Pharmaceutical (by Region), 2008-2014
  • Revenue Breakdown of Dongbao Pharmaceutical (by Region), 2008-2014
  • Operating Revenue Structure of Dongbao Pharmaceutical (by Industry), 2008-2014
  • Revenue Breakdown of Dongbao Pharmaceutical (by Industry), 2008-2014
  • Consolidated Gross Margin of Dongbao Pharmaceutical, 2008-2014
  • Gross Margin of Dongbao Pharmaceutical (by Industry), 2008-2014
  • Dongbao Pharmaceutical's Revenue from Top 5 clients and % of Total Revenue, 2009-2014
  • Dongbao Pharmaceutical's revenue from Recombinant Human Insulin and % of Total Revenue, 2009-2014
  • Gross Margin of Recombinant Human Insulin of Dongbao Pharmaceutical, 2009-2014
  • Revenue and Net Income of Dongbao Pharmaceutical, 2014-2017E
  • Revenue and Net Income of SL Pharm, 2008-2014
  • Operating Revenue Structure of SL Pharm (by Region), 2010-2014
  • Revenue Breakdown of SL Pharm (by Region), 2010-2014
  • Operating Revenue Structure of SL Pharm (by Industry), 2010-2014
  • Revenue Breakdown of SL Pharm (by Industry), 2010-2014
  • Consolidated Gross Margin of SL Pharm, 2008-2014
  • Gross Margin of SL Pharm (by Industry), 2010-2014
  • SL Pharm's Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
  • R&D Costs and % of Total Revenue of SL Pharm, 2008-2013
  • Output and Sales Volume of Biological and Biochemical Drugs of SL Pharm, 2011-2013
  • Revenue and Net Income of SL Pharm, 2014-2017E
  • Revenue and Net Income of Shihuan Bioengineering, 2008-2014
  • Operating Revenue Structure of Shihuan Bioengineering (by Region), 2009-2014
  • Revenue Breakdown of Shihuan Bioengineering (by Region), 2009-2014
  • Operating Revenue Structure of Shihuan Bioengineering (by Product), 2011-2014
  • Revenue Breakdown of Shihuan Bioengineering (by Product), 2011-2014
  • Consolidated Gross Margin of Shihuan Bioengineering, 2008-2014
  • Gross Margin of Shihuan Bioengineering (by Product), 2011-2014
  • Shihuan Bioengineering's Revenue from Top 5 Clients and % of Total Revenue, 2008-2014
  • Revenue and Gross Margin of Interleukin of Shihuan Bioengineering, 2008-2014
  • Revenue and Gross Margin of EPO of Shihuan Bioengineering, 2008-2014
  • Revenue and Gross Margin of G-CSF of Shihuan Bioengineering, 2011-2014
  • Revenue and Net Income of Shihuan Bioengineering, 2014-2017E
  • Comparison among Sales Growth Rates of Major Recombinant Protein Drugs of Sample Hospitals in China, 2005-2013
  • Market Competition of Various Genetically Engineered Drugs in China, as of end-Sep.2014
  • R&D of High-end Recombinant Protein Drugs in China (Partial), as of Sep.2014
Back to Top